# Central Venous Catheter Market

> Central Venous Catheter Market Research Report: Size, Share, Trend Analysis By Product Type (Non-tunneled Catheters, Tunneled Catheters), By Property (Non-Antimicrobial Catheters, Antimicrobial Catheters, and Others), By Design (Multi Lumen, Double Lumen, and Single Lumen), By Composition (Polyurethane, Silicone, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.85%
- **2025:** USD 2.71 Billion
- **2035:** USD 5.23 Billion
- **Key Players:** Teleflex Incorporated, ICU Medical, B. Braun Melsungen, Cook Medical, AngioDynamics, Vygon, Medtronic, Merit Medical Systems

**Report ID:** MRFR/MED/17659-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** October 27, 2026

**URL:** https://www.marketresearchfuture.com/reports/central-venous-catheter-market-19206

---

## Market Summary

The Global Central Venous Catheter Market size was valued at USD 1.338 Billion in 2024, and the market is projected to grow from USD 1.413 Billion in 2025 to USD 2.437 Billion by 2035, registering a CAGR of 5.6% during the forecast period 2026–2035. North America led the market with over 44.84% share, generating around USD 0.6 billion in revenue.
 
The increasing prevalence of chronic diseases, rising hospitalization rates, and growing demand for long-term intravenous therapies are major growth drivers for the Central Venous Catheter Market. Expanding adoption of minimally invasive vascular access procedures and advancements in catheter technologies are further supporting market expansion globally.
 
According to the World Health Organization, chronic diseases account for nearly 74% of global deaths annually, significantly increasing demand for critical care and long-term vascular access solutions. Rising cancer, kidney disease, and intensive care admissions continue accelerating adoption of central venous catheters worldwide.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising global cancer burden | +1.3% | Global | Long-term (≥4 yr) | [1] |
| Catheter reliance in hemodialysis | +1.1% | North America, Asia-Pacific | Long-term (≥4 yr) | [2][13] |
| CLABSI penalties and prevention mandates | +0.8% | North America, Europe | Short-term (≤2 yr) | [4][7] |
| Aging populations and ICU capacity growth | +0.9% | Global | Medium-term (2–4 yr) | [12] |
| Home infusion and parenteral nutrition | +0.7% | North America, Europe | Medium-term (2–4 yr) | [5] |
| Ultrasound and tip-location technology adoption | +0.6% | Global | Medium-term (2–4 yr) | [11] |

### Rising Global Cancer Burden

Oncology remains the single largest source of durable central access demand. IARC's GLOBOCAN 2022 data recorded about 20 million new cancer cases worldwide, and the agency projects annual incidence reaching 35 million by 2050 [1]. Multi-cycle chemotherapy, vesicant drugs, and extended biologic regimens all require reliable central lines, and each new patient on a long protocol typically receives at least one port or long-term catheter. This demographic pull supports volume growth largely independent of economic cycles.

### Catheter Reliance in Hemodialysis

Recurrent, high-acuity catheter demand is brought on by dialysis. About 80% of patients beginning hemodialysis in the US start with a central venous catheter instead of a mature fistula, according to the U.S. Renal Data System [2]. An estimated 850 million individuals worldwide suffer from renal disease, according to the International Society of Nephrology [13]. Through 2035, tunneled dialysis catheters will remain an essential component of the care route since arteriovenous access programs are still underfunded in many nations.

### CLABSI Penalties and Prevention Mandates

Financial accountability for infections is reshaping purchasing decisions. The 2022 SHEA/IDSA/APIC compendium update lists antimicrobial-impregnated catheters and chlorhexidine-based practices among recommended prevention strategies [4]. Combined with the CMS 1% payment penalty for poor HAC performers [7], these standards push hospitals toward premium coated devices and bundled insertion kits. The effect is short-term because most U.S. and European health systems already audit CLABSI rates quarterly.

### Aging Populations and ICU Capacity Growth

WHO projects that one in six people globally will be aged 60 or older by 2030 [12]. Older patients account for a disproportionate share of sepsis, cardiac surgery, and critical care admissions, where multi-lumen central access is standard. Governments in China, India, and the Gulf states expanded ICU bed capacity after the pandemic, and each new critical care bed carries recurring catheter consumption. Demand from this driver builds steadily over the medium term.

### Home Infusion and Parenteral Nutrition

Moving out of the hospital is therapy. The 9th edition of the Infusion Nurses Society's 2024 Standards of Practice updated recommendations for home and alternate-site infusion device selection and upkeep [5]. Catheters designed for prolonged residence, reduced occlusion rates, and simple management by non-specialists are necessary for patients discharged on long-term antibiotics or parenteral nourishment. Because home infusion eliminates inpatient bed days and maintains demand for durable access devices, payers like these models.

### Ultrasound and Tip-Location Technology Adoption

Point-of-care ultrasound and ECG-based tip confirmation are lowering the skill barrier for bedside placement. NICE guidance TA49 recommends two-dimensional ultrasound for elective central venous access [11], and most insertion bundles now reflect that standard. Nurse-led vascular access teams can place PICCs without fluoroscopy, which expands the number of facilities able to offer central access. Suppliers that bundle catheters with navigation systems capture higher value per procedure.

## Restraints

## Restraints Impact Analysis

Restraint impacts are directional estimates of downward pressure on growth in the Central Venous Catheter Market. They overlap with one another and with drivers, so they should not be subtracted directly from the headline CAGR.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Infection and thrombosis complications | −0.9% | Global | Medium-term (2–4 yr) | [3][9] |
| Pricing pressure from tenders and GPOs | −0.8% | China, Europe, North America | Short-term (≤2 yr) | [17] |
| EU MDR compliance burden | −0.5% | Europe | Medium-term (2–4 yr) | [14] |
| Ethylene oxide sterilization restrictions | −0.4% | North America | Medium-term (2–4 yr) | [15] |
| Substitution by midlines and peripheral devices | −0.6% | North America, Europe | Long-term (≥4 yr) | [10] |

### Infection and Thrombosis Complications

Clinical risk remains the market's persistent headwind. A 2013 Lancet meta-analysis found PICCs were associated with roughly 2.5 times the odds of deep vein thrombosis compared with other central catheters [9]. CDC guidelines urge prompt removal of unnecessary lines [3]. These findings encourage clinicians to shorten dwell times and avoid central access where possible, trimming per-patient device utilization.

### Pricing Pressure from Tenders and GPOs

High-volume medical supplies are now subject to volume-based procurement under China's National Healthcare Security Administration, and provincial tenders regularly result in significant price reductions [17]. Group purchasing organizations in the US negotiate multi-year contracts that reduce commodity single- and double lumen product margins. Average selling prices are eroding for suppliers who do not offer bundled services or distinctive coatings.

### EU MDR Compliance Burden

For legacy catheters, the Medical Device Regulation of the European Union mandates a notified body evaluation and new clinical evidence. The transition deadlines were extended to 2027 and 2028 by Regulation (EU) 2023/607 [14], but smaller manufacturers have already withdrawn low-volume versions due to the expense of recertification. Tender participation among European hospital groups may be slowed by a smaller range of products.

### Ethylene Oxide Sterilization Restrictions

Most catheters are sterilized with ethylene oxide. The U.S. EPA's March 2024 final rule tightened emission standards for commercial sterilization facilities, requiring significant control upgrades [15]. Plant closures and retrofits create capacity bottlenecks, and qualifying alternative methods such as radiation demands material compatibility testing that adds cost and time.

### Substitution by Midlines and Peripheral Devices

The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) recommends midlines or peripheral devices for many short infusion courses previously served by PICCs [10]. Hospitals adopting MAGIC-aligned protocols report fewer central line placements for therapies under two weeks. This substitution caps growth in low-acuity uses even as complex demand rises.

## Opportunities

## Central Venous Catheter Market Opportunities

Suppliers in the Central Venous Catheter Market can target five concrete opportunity areas over the forecast window.

### Next-Generation Antimicrobial and Antithrombogenic Surfaces

Premiums for evidence-based surface technologies will be paid by hospitals subject to CLABSI fines. The two main reasons for early removal, occlusion and infection, are addressed with coatings that mix antimicrobial compounds with non-leaching anti-clot chemistry. In European hospital groups and U.S. integrated delivery networks, suppliers that produce randomized outcome data may be granted formulary exclusivity.

### Emerging-Market Localization

India's Production Linked Incentive scheme for medical devices committed INR 3,420 crore to domestic manufacturing , and Saudi Arabia's Health Sector Transformation Program is expanding tertiary hospital capacity [25]. Multinationals that localize assembly can qualify for public tenders and offset pricing pressure through lower landed costs. ASEAN and Gulf markets remain underpenetrated in coated and power-injectable devices.

### Vascular Access Service and Data Models

Outcome-linked service contracts are beginning to replace product sales. Catheters, ultrasonography, tip-location systems, and staff training can all be bundled by suppliers into subscription plans that are charged based on CLABSI reduction or insertion success. Hospitals can employ device-level data collected by navigation software and unique device identifiers to provide analytics for high-quality reporting, providing vendors with a steady stream of income beyond disposables.

### Home Parenteral Nutrition and Alternate-Site Care

Growth in fluid and nutrition administration favors catheters designed for self-care, with simplified dressing protocols and occlusion-resistant valves. Partnerships with home infusion pharmacies offer suppliers direct channel access to long-dwell patients who were historically reached only through hospital purchasing.

### Outpatient Port Placement

Oncology practices and [ambulatory surgery centers](https://www.marketresearchfuture.com/reports/ambulatory-surgery-centers-market-65898) are taking on port implantation to reduce hospital scheduling delays. Compact port kits, low-profile designs, and pediatric sizes suited to office-based interventional suites represent a distinct product niche with favorable pricing.

## Future Outlook

## Central Venous Catheter Market Future Outlook

Four themes will define competition in the Central Venous Catheter Market through 2035.

### AI-Assisted Insertion and Navigation

Ultrasound systems with automated vessel detection and depth measurement are moving into bedside use. Combined with ECG tip confirmation, these tools can reduce malposition and repeat attempts. WHO projects a global shortfall of about 10 million health workers by 2030 [23], so technology that lets less experienced clinicians place lines safely will command strong demand.

### Site-of-Care Migration

Therapy continues to shift toward homes, infusion centers, and ambulatory surgery suites. IARC's projection of 35 million annual cancer cases by 2050 [1] implies outpatient chemotherapy capacity must expand substantially. Devices engineered for long dwell and low-maintenance care will capture a growing share of spending.

### Outcome-Based Procurement

Health systems increasingly evaluate suppliers on total cost of care rather than unit price. With a CLABSI adding roughly USD 48,000 per case [6], vendors able to document infection and occlusion reductions can defend pricing. Expect more risk-sharing contracts and data-driven vendor scorecards.

### Sustainability and Sterilization Transition

EPA's 2024 ethylene oxide rule [15] and hospital decarbonization targets are pushing manufacturers toward alternative sterilization, DEHP-free materials, and reduced packaging. Suppliers in the Central Venous Catheter Market that qualify radiation-compatible polymers early will avoid supply disruptions and meet emerging environmental tender criteria.

## Segment Insights

## Central Venous Catheter Market Segmentation

Market Research Future segments the Central Venous Catheter Market by lumen type and application.

### By Lumen Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| single lumen | USD 0.54 Billion | Long-term chemotherapy and antibiotic therapy |
| double lumen | 45.4% share | Hemodialysis and multi-drug protocols |
| triple lumen | 23.6% share | Critical care and perioperative monitoring |
| multi-lumen | 9.3% CAGR | Complex ICU regimens |

Within the Central Venous Catheter Market, double lumen catheters lead with a 45.4% share because hemodialysis requires simultaneous withdrawal and return, and oncology protocols benefit from separating incompatible drugs. Triple-lumen devices remain standard in intensive care and cardiac surgery. Multi-lumen designs grow fastest at a 9.3% CAGR as clinicians consolidate vasopressors, sedation, nutrition, and sampling through a single insertion site, reducing infection exposure. Single-lumen products serve simpler long-dwell therapies where fewer hubs lower contamination risk.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| drug administration | 56.4% share | Chemotherapy, antibiotics, and biologics |
| Fluid and nutrition administration | 10.4% CAGR | Home and ICU parenteral nutrition |
| blood transfusion | 15.2% share | Oncology and hematology support |
| Diagnostics and testing | USD 0.29 Billion | Repeated blood sampling and hemodynamic monitoring |

Drug delivery sits at the core of the Central Venous Catheter Market, with drug administration holding a 56.4% share as vesicant chemotherapy and extended antibiotic courses depend on stable central access. Fluid and nutrition administration expands fastest at a 10.4% CAGR, reflecting home parenteral nutrition growth and earlier hospital discharge. Blood transfusion demand tracks hematologic cancer volumes, while diagnostics and testing benefit from repeated sampling needs in critical care.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.6% share | CLABSI penalties, dialysis volume, home infusion |
| Europe | 27.4% share | MDR recertification, nurse-led PICC teams |
| Asia-Pacific | 8.9% CAGR | ICU expansion, local manufacturing, cancer care |
| South America | USD 0.14 Billion | Public hospital tenders, oncology access |
| Middle East & Africa | 6.2% CAGR | Tertiary hospital build-out, medical tourism |
| Total | USD 2.71 Billion (2025) | — |

Regional dynamics in the Central Venous Catheter Market reflect differences in dialysis access practice, oncology infrastructure, infection-control enforcement, and procurement structure.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 86.2% share of region | CMS HAC penalties and ESKD catheter use |
| Canada | USD 0.09 Billion | Provincial oncology programs |
| Mexico | 7.4% CAGR | IMSS hospital modernization |

The United States dominates regional consumption because of its dialysis population, high chemotherapy volumes, and reimbursement penalties tied to CLABSI performance [2][7]. CDC's National Healthcare Safety Network publishes annual HAI progress reports that hospitals use to benchmark infection rates [8], sustaining demand for premium coated devices across the Central Venous Catheter Market. Canada's single-payer tenders favor established suppliers, while Mexico is modernizing public hospital infrastructure.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 22.8% share of region | Large hospital base and oncology centers |
| UK | USD 0.12 Billion | NHS nurse-led vascular access services |
| France | 16.1% share of region | Home hospitalization (HAD) programs |
| Italy | 5.9% CAGR | Aging population and dialysis demand |
| Spain | USD 0.07 Billion | Regional tender consolidation |
| Nordic Countries | 6.4% share of region | High adoption of ultrasound-guided insertion |
| Russia | 4.8% CAGR | Import substitution policy |
| Rest of Europe | 13.0% share of region | EU cohesion fund hospital upgrades |

Europe's market is shaped by the MDR transition and strong public procurement frameworks [14]. The UK and Nordic health systems pioneered nurse-led PICC insertion, which lowered placement costs and broadened access. Germany and France support high oncology and home-hospitalization volumes, while Southern European tenders increasingly weigh infection outcome data alongside price.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 38.5% share of region | ICU expansion under volume-based procurement |
| India | 11.2% CAGR | PLI manufacturing incentives and PM-JAY coverage |
| Japan | USD 0.13 Billion | Super-aged population |
| South Korea | 7.9% share of region | Advanced oncology infrastructure |
| ASEAN | 10.1% CAGR | Private hospital growth |
| Rest of Asia-Pacific | USD 0.04 Billion | Australian dialysis and oncology care |

Asia-Pacific is the fastest-growing region in the Central Venous Catheter Market. China combines rapid ICU capacity growth with aggressive price tenders [17], favoring domestic producers of commodity lines. India pairs manufacturing incentives  with expanded insurance coverage, lifting procedure volumes. Japan's aging population sustains steady demand for long-term ports and dialysis access.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.7% share of region | SUS oncology and dialysis networks |
| Argentina | 6.9% CAGR | Private hospital investment |
| Rest of South America | 22.4% share of region | Public health system tenders |

Brazil anchors regional demand through its public SUS network, which funds a large share of dialysis and chemotherapy. Currency volatility and ANVISA registration timelines slow new product entry, so incumbents with local distribution hold durable positions. Argentina's private sector is gradually adopting coated catheters.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 29.5% share of region | Vision 2030 health transformation |
| UAE | 8.3% CAGR | Medical tourism and specialty hospitals |
| South Africa | USD 0.02 Billion | Private hospital groups |
| Egypt | 7.8% CAGR | Universal health insurance rollout |
| Rest of MEA | 25.0% share of region | Donor-funded hospital projects |

Gulf states are building tertiary oncology and cardiac centers under national transformation programs [25], creating demand for premium devices. Saudi Arabia leads regional spending, while the UAE benefits from medical tourism. Across Africa, access remains constrained by budgets and workforce shortages, though Egypt's insurance reforms are broadening procedure coverage.

## Competitive Benchmarking

## Competitive Benchmarking

The Central Venous Catheter Market is moderately concentrated. Market Research Future estimates a Herfindahl-Hirschman Index of roughly 1,000–1,200, with the top five suppliers holding an estimated 55–62% of revenue. Global leaders dominate coated, power-injectable, and navigation-integrated products, while regional manufacturers in China, India, and Latin America compete on price in commodity single and double lumen lines.

| Company | Est. Revenue Share Range | Key Offerings for Central Venous Catheter Market | Strategic Positioning |
| --- | --- | --- | --- |
| Becton, Dickinson and Company (BD) | ~20–24% | PowerPICC catheters, PowerPort implanted ports, Site-Rite ultrasound | Broadest vascular access portfolio; critical care expansion via Edwards acquisition |
| Teleflex Incorporated | ~14–17% | Arrow CVC and PICC lines, antimicrobial-coated catheters, tip-location systems | Infection-prevention differentiation; corporate restructuring underway |
| ICU Medical | ~8–11% | Central venous catheters, ports, and infusion systems (incl. former Smiths Medical lines) | Integrated infusion and access offering |
| B. Braun Melsungen | ~7–10% | Certofix CVCs, Celsite ports | Strong European hospital presence |
| Cook Medical | ~4–6% | Spectrum antimicrobial CVCs, PICCs | Interventional radiology channel |
| AngioDynamics | ~4–6% | BioFlo PICCs and ports with thromboresistant technology | Focus on occlusion reduction |
| Vygon | ~3–5% | Pediatric and neonatal CVCs, PICCs | Specialist in pediatric access |
| Medtronic | ~3–5% | Hemodialysis catheters | Renal care channel |
| Merit Medical Systems | ~2–4% | Dialysis catheters, PICC and port systems | Acquisitive growth in dialysis access |
| Terumo Corporation | ~2–3% | Central venous catheters and ports | Asia-Pacific distribution strength |
| Argon Medical Devices | ~1–2% | Vascular access catheters and accessories | Value-focused interventional portfolio |

## Recent News & Developments

## Recent News & Developments

Corporate restructuring and regulation shaped the Central Venous Catheter Market between 2023 and 2025.

- European Commission (March 2023): Adopted Regulation (EU) 2023/607, extending MDR transition deadlines and preventing near-term withdrawal of legacy catheter certificates [14]
- Merit Medical Systems (June 2023): Acquired AngioDynamics' dialysis catheter portfolio and BioSentry tract sealant system, strengthening its long-term access position [22]
- Infusion Nurses Society (January 2024): Published the 9th edition of the Infusion Therapy Standards of Practice, updating device selection and CLABSI prevention guidance [5]
- U.S. EPA (March 2024): Finalized tighter ethylene oxide emission standards for commercial sterilizers, affecting catheter sterilization capacity [15]
- BD (September 2024): Completed its USD 4.2 billion acquisition of Edwards Lifesciences' Critical Care business, adding hemodynamic monitoring to its acute-care franchise [19]
- ICU Medical (January 2025): Announced a joint venture with Otsuka Pharmaceutical Factory for IV solutions, sharpening its focus on infusion and vascular access consumables [21]
- Teleflex (February 2025): Announced plans to separate into two companies, a move with implications for its Arrow vascular access franchise [20]
- BD (July 2025): Announced the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, refocusing BD on medical technology including vascular access [18]

## Report Scope

| Report Attribute/Metric | Details |
| --- | --- |
| Market Scope | Central Venous Catheter Market segmented by lumen type (single lumen, double lumen, triple lumen, multi-lumen), application (drug administration, fluid and nutrition administration, blood transfusion, diagnostics and testing), and region. |
| Study Period | 2021-2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 2.71 Billion |
| Market Size in 2035 | USD 5.23 Billion |
| CAGR (2026–2035) | 6.85% |
| Fastest Growing Segments | multi-lumen (lumen type); fluid and nutrition administration (application); Asia-Pacific (region) |
| Regions Covered | Asia-Pacific (region); North America, Europe, APAC, South America, MEA |
| Companies Profiled | BD, Teleflex, ICU Medical, B. Braun, Cook Medical, AngioDynamics, Vygon, Medtronic, Merit Medical, Terumo, Argon Medical Devices |
| Valuation Currency | USD Billion |
| Methodology | Bottom-up production + top-down trade validation; 42-country coverage; primary interviews with 85+ industry participants; secondary sources include customs data, company filings, regulatory databases |

## Frequently Asked Questions

**Q: How should hospital buyers evaluate antimicrobial-coated catheters in the Central Venous Catheter Market?**
A: Buyers should request randomized or large real-world outcome data on CLABSI and occlusion, not just in vitro results. Coating duration should match expected dwell time, since short-lived agents add little value on long-term lines [4].

**Q: What regulatory pathway applies to new entrants in the Central Venous Catheter Market in the United States?**
A: Most central catheters are Class II devices cleared through the FDA 510(k) pathway. New coatings or drug-eluting claims can trigger additional performance and biocompatibility testing, lengthening time to launch.

**Q: Why are power-injectable catheters becoming a procurement default?**
A: Oncology patients need repeated contrast-enhanced CT scans, and power-rated lines typically tolerate injections of about 5 mL per second. Standardizing on them avoids placing a second access device solely for imaging.

**Q: How do group purchasing organizations influence pricing in the Central Venous Catheter Market?**
A: Most U.S. hospitals buy through GPO contracts that award multi-year, sole- or dual-source agreements. Suppliers in the Central Venous Catheter Market often bundle catheters with insertion kits and training to secure these awards.

**Q: What role do vascular access teams play in device selection?**
A: Dedicated nurse-led teams increasingly control catheter choice, insertion technique, and maintenance protocols. Their preference for ultrasound-compatible, easy-to-thread devices makes them a key sales audience alongside procurement [5].

**Q: How is ECG-based tip confirmation changing insertion workflows?**
A: ECG guidance confirms catheter tip position at the bedside, often removing the need for a confirmatory chest X-ray. This shortens time to first infusion and frees radiology capacity.

**Q: How does pediatric catheter selection differ from adult practice?**
A: Pediatric patients need smaller French sizes and softer materials such as silicone to protect fragile vessels. Specialists like Vygon focus on neonatal lines where adult products are unsuitable.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/central-venous-catheter-market-19206*